Emerging drugs for idiopathic pulmonary fibrosis

• THANNICKAL VJ, TOEWS GB,WHITE ES, LYNCH JP 3rd, MARTINEZ FJ: Mechanisms of pulmonary fibrosis. Ann. Rev. Med. (2004) 55:395–417.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: American Thoracic Society: idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. (2000) 161(2 Pt 1):646–664.
   PubMed Web of Science ®Google Scholar
• AMERICAN THORACIC SOCIETY; EUROPEAN RESPIRATORY SOCIETY: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. (2002) 165(2):277–304.
   PubMedGoogle Scholar
• FLAHERTY KR, TRAVIS WD, COLBY TV et al.: Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. (2001) 164(9):1722–1727.
   PubMed Web of Science ®Google Scholar
• KATZENSTEIN AL, ZISMAN DA, LITZKY LA, NGUYEN BT, KOTLOFF RM: Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am. J. Surg. Pathol (2002) 26(12):1567–1577.
   PubMed Web of Science ®Google Scholar
• SELMAN M, THANNICKAL VJ, PARDO A et al.: Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs (2004) 64(4):405–430.
   PubMed Web of Science ®Google Scholar
• THANNICKAL VJ, FLAHERTY KR, MARTINEZ FJ, LYNCH JP 3rd: Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin. Pharmacother. (2004) 5(8):1671–1686.
   PubMed Web of Science ®Google Scholar
• COLLARD HR, KING TE Jr: Demystifying idiopathic interstitial pneumonia. Arch. Intern. Med. (2003) 163(1):17–29.
   PubMed Web of Science ®Google Scholar
• SELMAN M, KING TE, PARDO A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. (2001) 134(2):136–151.
   PubMed Web of Science ®Google Scholar
• GROSS TJ, HUNNINGHAKE GW: Idiopathic pulmonary fibrosis. N Engl J. Med. (2001) 345(7):517–525.
   PubMed Web of Science ®Google Scholar
• COULTAS DB, ZUMWALT RE, BLACK WC, SOBONYA RE: The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. (1994) 150(4):967–972.
   PubMed Web of Science ®Google Scholar
• MANNINO DM, ETZEL RA, PARRISH RG: Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. Am. J. Respir. Crit. Care Med. (1996) 153(5):1548–1552.
   PubMed Web of Science ®Google Scholar
• TURNER-WARWICK M, BURROWS B, JOHNSON k Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax (1980) 35(8):593–599.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ DA, HELMERS RA, GALVIN JR et al.: Determinants of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (1994) 149(2 Pt 1):450–454.
   PubMed Web of Science ®Google Scholar
• MASON RJ, SCHWARZ MI, HUNNINGHAKE GW, MUSSON RA: NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present and future. Am. J. Respir. Crit. Care Med. (1999) 160(5 Pt 1):1771–1777.
   PubMedGoogle Scholar
• CARRINGTON CB, GAENSLER EA, COUTURE, FITZGERALD MX, GUPTA RG: Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl. J. Med. (1978) 298(15):801–809.
   PubMed Web of Science ®Google Scholar
• FLAHERTY KR, TOEWS GB, TRAVIS WD et al.: Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur. Respir. J. (2002) 19(2):275–283.
   PubMed Web of Science ®Google Scholar
• WATTERS LC, KING TE, SCHWARZ MI et al.: A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. (1986) 133(1):97–103.
   PubMed Web of Science ®Google Scholar
• FLAHERTY KR, TOEWS GB, LYNCH JP 3rd et al.: Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. (2001) 110(4):278–282.
   PubMed Web of Science ®Google Scholar
• RAGHU G, DEPASO WJ, CAIN K et al.:Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. (1991) 144(2):291–296.
   PubMed Web of Science ®Google Scholar
• JOHNSON MA, KWAN S, SNELL NJ et al.: Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax (1989) 44(4):280–288.
   PubMed Web of Science ®Google Scholar
• ZISMAN DA, LYNCH JP 3rd, TOEWS GB et al.: Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest (2000) 117(0:1619–1626.
   PubMed Web of Science ®Google Scholar
• WARE LB, MATTHAY MA: The acute respiratory distress syndrome. N Engl J. Med. (2000) 342(18):1334–1349.
   PubMed Web of Science ®Google Scholar
• RAGHU G, BROWN KK, BRADFORD WZ et al.: A placebo-controlled trial of interferon gamma-lb in patients with idiopathic pulmonary fibrosis. N Engl J. Med. (2004) 350(2):125–133.
   PubMed Web of Science ®Google Scholar
• LAMA VN, FLAHERTY KR, TOEWS GB et al.: Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. (2003) 168(9):1084–1090.
   PubMed Web of Science ®Google Scholar
• AZUMA A, NUKIWA T, TSUBOI E et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2005) 171(9):1040–1047.
   PubMed Web of Science ®Google Scholar
• MURPHY KM, OUYANG W, FARRAR JD et al.: Signaling and transcription in T helper development. Ann. Rev. Immunol (2000) 18:451–494.
   PubMed Web of Science ®Google Scholar
• WALLACE WA, RAMAGE EA, LAMB D, HOWIE SE: A type 2 (TH2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin. Exp. Immunol (1995) 101(3):436–441.
   PubMed Web of Science ®Google Scholar
• WYNN TA: Fibrotic disease and the T(H)1 /T(H)2 paradigm. Nat. Rev. Immunol. (2004) 4(8):583–594.
   PubMed Web of Science ®Google Scholar
• PRIOR C, HASLAM PL: In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin. Exp. Immunol. (1992) 88(2):280–287.
   PubMed Web of Science ®Google Scholar
• ZIESCHE R, HOFBAUER E, WITTMANN K, PETKOV V, BLOCK LH: A preliminary study of long-term treatment with interferon gamma-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl. J. Med. (1999) 341(17):1264–1269.
   PubMed Web of Science ®Google Scholar
• ULLOA L, DOODY J, MASSAGUE J: Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature (1999) 397(6721):710–713.
   PubMed Web of Science ®Google Scholar
• FLANDERS KC, SULLIVAN CD, FUJII M et al.: Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am. J. Pathol. (2002) 160(3):1057–1068.
   PubMed Web of Science ®Google Scholar
• ROBERTS AB, PIEK E, BOTTINGER EP et al.: Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? Chest (2001) 120(1 Suppl.):435–475.
   Google Scholar
• ROSENBLOOM J, FELDMAN G, FREUNDLICH B, JIMENEZ SA: Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum. (1986) 29(7):851–856.
   PubMed Web of Science ®Google Scholar
• ELIAS JA, JIMENEZ SA, FREUNDLICH B: Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation. Am. Rev. Respir. Dis. (1987) 135(1):62–65.
   PubMed Web of Science ®Google Scholar
• ELIAS JA, FREUNDLICH B, ADAMS S, ROSENBLOOM J: Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma. Ann. NY Acad. Sci. (1990) 580:233–244.
   PubMed Web of Science ®Google Scholar
• CHEN ES, GREENLEE BM, WILLS-KARP M, MOLLER DR: Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am. J. Respir. Cell Md. Biol. (2001) 24(5):545–555.
   PubMed Web of Science ®Google Scholar
• GURUJEYALAKSHMI G, GIRI SN: Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp. Lung Res. (1995) 21(5):791–808.
   PubMed Web of Science ®Google Scholar
• HONORE I, NUNES H, GROUSSARD 0 et al.: Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2003) 167(7):953–957.
   PubMed Web of Science ®Google Scholar
• PHELPS DT, DENEKE SM, DALEY DL, FANBURG BL: Elevation of glutathione levels in bovine pulmonary artery endothelial cells by N-acetylcysteine. Am. J.Respir. Cell Md. Biol. (1992) 7(3):293–299.
   PubMed Web of Science ®Google Scholar
• BOROK Z, BUHL R, GRIMES GJ et al.:Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet (1991) 338(8761):215–216.
   Google Scholar
• MEYER A, BUHL R, MAGNUSSEN H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. (1994) 7(3):431–436.
   Google Scholar
• WHITE AC, THANNICKAL VJ, FANBURG BL: Glutathione deficiency in human disease. J. Nutr. Biochem. (1994) 5:218–226.
   Web of Science ®Google Scholar
• RINALDO J, GOLDSTEIN RH, SNIDER GL: Modification of oxygen toxicity after lung injury by bleomycin in hamsters. Am. Rev. Respir. Dis. (1982) 126(6):1030–1033.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA JM, LEVIN JR, HYDE DM, GIRT SN: Repeated exposures to enzyme-generated oxidants cause alveolitis, epithelial hyperplasia, and fibrosis in hamsters. Am. J. Pathol (1991) 139(6):1485–1499.
   PubMed Web of Science ®Google Scholar
• MANOURY B, NENAN S, LECLERC 0 et al.: The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir. Res. (2005) 6(1):11.
   PubMed Web of Science ®Google Scholar
• SHAHZEIDI S, SARNSTRAND B, JEFFERY PK, MCANULTY RJ, LAURENT GJ: Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur. Respir. J. (1991) 4(7):845–852.
   PubMed Web of Science ®Google Scholar
• MACNEE W, RAHMAN I: Oxidants/ antioxidants in idiopathic pulmonary fibrosis. Thorax (1995) 50\(Suppl. 1):553–558.
   Google Scholar
• RAHMAN I, SKWARSKA E, HENRY M et al.: Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic. Biol Med. (1999) 27(1-2):60–68.
   PubMed Web of Science ®Google Scholar
• CANTIN AM, NORTH SL, FELLS GA, HUBBARD RC, CRYSTAL RG: Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J. Clin. Invest. (1987) 79(6):1665–1673.
   PubMed Web of Science ®Google Scholar
• CANTIN AM, HUBBARD RC, CRYSTAL RG: Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. (1989) 139(2):370–372.
   PubMed Web of Science ®Google Scholar
• WAGHRAY M, GUI Z, HOROWITZ JC et al.: Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J(2005) 19(7):854–856.
   PubMed Web of Science ®Google Scholar
• THANNICKAL VJ, LEE DY, WHITE ES et al.: Myofibroblast differentiation by transforming growth factor-betal is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. (2003) 278(14):12384–12389.
   PubMed Web of Science ®Google Scholar
• THANNICKAL VJ, FANBURG BL: Activation of an H202-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1.1 Biol. Chem. (1995) 270(51):30334–30338.
   Web of Science ®Google Scholar
• THANNICKAL VJ, DAY RM, KLINZ SG et al.: Ras-dependent and -independent regulation of reactive oxygen species by mitogenic growth factors and TGF-betal. FASEB J (2000) 14(12):1741–1748.
   PubMed Web of Science ®Google Scholar
• BEHR J, MATER K, DEGENKOLB B, KROMBACH F, VOGELMEIER C: Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. (1997) 156(61:1897–1901.
   PubMed Web of Science ®Google Scholar
• IYER SN, HYDE DM, GIRT SN: Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation (2000) 24(5):477–491.
   PubMed Web of Science ®Google Scholar
• OKU H, NAKAZATO H, HORIKAWA T, TSURUTA Y, SUZUKI R: Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol (2002) 446(1-3):167–176.
   PubMed Web of Science ®Google Scholar
• HALE ML, MARGOLIN SB, KRAKAUER T, ROY CJ, STILES BG: Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect. Immun. (2002) 70(6):2989–2994.
   PubMed Web of Science ®Google Scholar
• NAKAZATO H, OKU H, YAMANE S, TSURUTA Y, SUZUKI R: A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur. j Pharmacol (2002) 446(1-3):177–185.
   PubMed Web of Science ®Google Scholar
• DI SARIO A, BENDIA E, SVEGLIATI BARONI G et al.: Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. 1 Hepato/. (2002) 37(5):584–591.
   Google Scholar
• HEWITSON TD, KELYNACK KJ, TAIT MG et al.: Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J. NephroL (2001) 14(6):453–460.
   PubMed Web of Science ®Google Scholar
• IYER SN, GURUJEYALAKSHMI G, GIRT SN: Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. PharmacoL Exp. Ther. (1999) 291(1):367–373.
   PubMed Web of Science ®Google Scholar
• GURUJEYALAKSHMI G, HOLLINGER MA, GIRT SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol. (1999) 276(2 Pt 1):L311–L318.
   PubMedGoogle Scholar
• GIRT SN, LEONARD S, SHI X, MARGOLIN SB, VALLYATHAN V: Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. PathoL lbxicoL OncoL (1999) 18(3):169–177.
   PubMed Web of Science ®Google Scholar
• MISRA HP, RABIDEAU C: Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. (2000) 204(1-2):119–126.
   PubMed Web of Science ®Google Scholar
• IYER SN, WILD JS, SCHIEDT MJ et al.: Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. (1995) 125(6):779–785.
   PubMed Web of Science ®Google Scholar
• KEHRER JP, MARGOLIN SB: Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. ToxicoL Lett. (1997) 90(2-3):125–132.
   PubMed Web of Science ®Google Scholar
• DOSANJH AK, WAN B, THRONDSET W, SHERWOOD S, MORRIS RE: Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant. Proc. (1998) 30(5):1910–1911.
   PubMed Web of Science ®Google Scholar
• SHIMIZU T, KURODA T, HATA S et al.: Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. (1998) 54(1):99–109.
   PubMed Web of Science ®Google Scholar
• AL-BAYATI MA, XIE Y, MOHR FC, MARGOLIN SB, GIRT SN: Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem. PharmacoL (2002) 64(3):517–525.
   PubMed Web of Science ®Google Scholar
• TADA S, NAKAMUTA M, ENJOJI M et al.: Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. (2001) 28(7):522–527.
   PubMed Web of Science ®Google Scholar
• GARCIA L, HERNANDEZ I, SANDOVAL A et al.: Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. (2002) 37(0:797–805.
   PubMed Web of Science ®Google Scholar
• WALLER JR, MURPHY GJ, METCALFE MS et al.: Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury. Transplant. Proc. (2001) 33(7-8):3816–3818.
   PubMed Web of Science ®Google Scholar
• MIRIC G, DALLEMAGNE C, ENDRE Z et al.: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. PharmacoL (2001) 133(5):687–694.
   PubMed Web of Science ®Google Scholar
• RAGHU G, JOHNSON WC, LOCKHART D, MAGETO Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. (1999) 159(4 Pt 1):1061–1069.
   PubMed Web of Science ®Google Scholar
• NAGAI S, HAMADA K, SHIGEMATSU M et al.: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. (2002) 41(12):1118–1123.
   PubMed Web of Science ®Google Scholar
• GAHL WA, BRANTLY M, TROENDLE J et al.: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. (2002) 76(3):234–242.
   PubMed Web of Science ®Google Scholar
• UGUCCIONI M, PULSATELLI L, GRIGOLO B et al.: Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. PathoL (1995) 48(0330–334.
   PubMed Web of Science ®Google Scholar
• GIAID A, MICHEL RP, STEWART DJ et al.: Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet (1993) 341(8860):1550–1554.
   PubMed Web of Science ®Google Scholar
• SALEH D, FURUKAWA K, TSA0 MS et al.: Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am. J. Respir. Cell Mot Biol. (1997) 16(2):187–193.
   PubMed Web of Science ®Google Scholar
• CAMBREY AD, HARRISON NK, DAWES KE et al.: Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell Mot Biol. (1994) 11(4):439–445.
   PubMed Web of Science ®Google Scholar
• SAITO H, NAKAMURA H, KATO S et al.: Percutaneous in vivo gene transfer to the peripheral lungs using plasmid-liposome complexes. Am. J. Physiol. Lung Cell Mol. Physiol. (2000) 279(4):L651–L657.
   PubMed Web of Science ®Google Scholar
• HOCHER B, SCHWARZ A. FAGAN KA et al.: Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. Respir. Cell Mol. Biol. (2000) 23(1):19–26.
   PubMed Web of Science ®Google Scholar
• PEACOCK AJ, DAWES KE, SHOCK A et al.: Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am. J. Respir. Cell Mot Biol. (1992) 7(5):492–499.
   PubMed Web of Science ®Google Scholar
• SHAHAR I, FIREMAN E, TOPILSKY M et al.: Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int. J. ImmunopharmacoL (1999) 21 (11):759–775.
   Google Scholar
• SHI-WEN X, CHEN Y, DENTON CP et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell (2004) 15(6):2707–2719.
   PubMed Web of Science ®Google Scholar
• XU S, DENTON CP, HOLMES A et al.: Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J. Cardiovasc. PharmacoL (1998) 31(Suppl. 1):5360–5363.
   Google Scholar
• MAYER DC, LEINWAND LA: Sarcomeric gene expression and contractility in myofibroblasts. J. Cell Biol. (1997) 139(6):1477–1484.
   Google Scholar
• GASULL X, BATALLER R, GINES P et al.: Human myofibroblastic hepatic stellate cells express Ca(2) -activated K(*) channels that modulate the effects of endothelin-1 and nitric oxide. J. Hepatol. (2001) 35(0:739–748.
   PubMed Web of Science ®Google Scholar
• SHICHIRI M, SEDIVY JM, MARUMO F, HIRATA Y: Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol. EndocrinoL (1998) 12(2):172–180.
   PubMed Web of Science ®Google Scholar
• SHI-WEN X, DENTON CP, DASH WOOD MR et al.: Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J. Invest. DermatoL (2001) 116(3):417–425.
   PubMed Web of Science ®Google Scholar
• WENDEL M, PETZOLD A. KOSLOWSKI R et al.: Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem. Cell Biol. (2004) 122(5):507–517.
   PubMed Web of Science ®Google Scholar
• PARK SH, SALEH D, GIAID A, MICHEL RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. (1997) 156(2 Pt 1):600–608.
   PubMed Web of Science ®Google Scholar
• MUTSAERS SE, MARSHALL RP GOLDSACK NR, LAURENT GJ, MCANULTY RJ: Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. PharmacoL Ther. (1998) 11(2-3):221–225.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N EngL J. Med. (2002) 346(12):896–903.
   PubMed Web of Science ®Google Scholar
• PIGUET PF: Is 'tumor necrosis factor' the major effector of pulmonary fibrosis? Eur. Cytokine Netzu (1990) 1(4):257–258.
   PubMedGoogle Scholar
• LUNDBLAD LK, THOMPSON-FIGUEROA J, LECLAIR T et al.: TNF-{alpha} over-expression in lung disease: a single cause behind a complex phenotype. Am. J. Respir. Crit. Care Med. (2005) 171(12):1363–1370.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, COLLART MA, GRAU GE, KAPANCI Y, VASSALLI P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. (1989) 170(3):655–663.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, VESIN C: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. (1994) 7(3):515–518.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, COLLART MA, GRAU GE, SAPPINO AP, VASSALLI P: Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature (1990) 344(6263):245–247.
   Google Scholar
• ORTIZ LA, LASKY J, LUNGARELLA G et al.: Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am. J. Respir. Cell Mot Biol. (1999) 20(4):825–833.
   PubMed Web of Science ®Google Scholar
• LIU JY, BRASS DM, HOYLE GW, BRODY AR: TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am. J. PathoL (1998) 153(6):1839–1847.
   PubMed Web of Science ®Google Scholar
• KUROKI M, NOGUCHI Y, SHIMONO M et al.: Repression of bleomycin-induced pneumopathy by TNE j ImmunoL (2003) 170(1):567–574.
   Web of Science ®Google Scholar
• FUJITA M, SHANNON JM, MORIKAWA 0 et al.: Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am. J. Respir. Cell MoL Biol. (2003) 29(6):669–676.
   PubMed Web of Science ®Google Scholar
• SOLIS-HERRUZO JA, BRENNER DA, CHOJKIER M: Tumor necrosis factor alpha inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J. Biol. Chem. (1988) 263(12):5841–5845.
   PubMed Web of Science ®Google Scholar
• KAHARI VM, CHEN YQ, SU MW, RAMIREZ F, UITTO J: Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J. Clin. Invest. (1990) 86(5):1489–1495.
   PubMed Web of Science ®Google Scholar
• SIWIK DA, CHANG DL, COLUCCI WS: Interleukin-lbeta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ. Res. (2000) 86(12):1259–1265.
   PubMed Web of Science ®Google Scholar
• GREENWEL P, TANAKA S, PENKOV D et al.: Tumor necrosis factor alpha inhibits type I collagen synthesis through repressive CCAAT/enhancer-binding proteins. MoL Cell. Biol. (2000) 20(3):912–918.
   PubMed Web of Science ®Google Scholar
• HAN YP, TUAN TL, WU H, HUGHES M, GARNER WL: TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J. Cell Sci. (2001) 114(Pt 1):131–139.
   PubMed Web of Science ®Google Scholar
• RAPALA KT, VAHA-KREULA MO, HEINO JJ, VUORIO El, LAATO MK: Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts. Experientia (1996) 52(1):70–74.
   Google Scholar
• KON A, VINDEVOGHEL L, KOUBA DJ et al.: Cooperation between SMAD and NF-kappaB in growth factor regulated type VII collagen gene expression. Oncogene (1999) 18(10):1837–1844.
   PubMed Web of Science ®Google Scholar
• CHOU DH, LEE W, MCCULLOCH CA: TNF-alpha inactivation of collagen receptors: implications for fibroblast function and fibrosis. J. ImmunoL (1996) 156(11):4354–4362.
   PubMed Web of Science ®Google Scholar
• WANG R, ALAM G, ZAGARIYA A et al.: Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J. Cell. PhysioL (2000) 185(2):253–259.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, RIBAUX C, KARPUZ V, GRAU GE, KAPANCI Y: Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am. J. PathoL (1993) 143(3):651–655.
   PubMed Web of Science ®Google Scholar
• NASH JR, MCLAUGHLIN PJ, BUTCHER D, CORBIN B: Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology (1993) 22(4):343–347.
   PubMed Web of Science ®Google Scholar
• WHYTE M, HUBBARD R, MELICONI R et al.: Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am. J. Respir. Crit. Care Med. (2000) 162(2 Pt 1):755–758.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI Y, ARAKI K, VESIN C et al.: Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. (1995) 96(1):250–259.
   PubMed Web of Science ®Google Scholar
• SIME PJ, MARR RA, GAULDIE D et al.: Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-betal and myofibroblasts. Am. J. PathoL (1998) 153(3):825–832.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, MAINI RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann. Rev. ImmunoL (2001) 19:163–196.
   PubMed Web of Science ®Google Scholar
• NIDEN A. KOSS M, BOYLEN CT, WILCOX A: An open label pilot study to determine the potential efficacy of TNFR:Fc (Enbrel, Etanercept) in the treatment of usual interstitial pneumonitis. Am. J. Respir. Crit. Care Med. (2002) 165(8):A728.
   Google Scholar
• SAVAGE DG, ANTMAN KH: Imatinib mesylate-a new oral targeted therapy. N Engl. J. Med. (2002) 346(9):683–693.
   PubMed Web of Science ®Google Scholar
• DANIELS CE, WILKES MC, EDENS M et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. Clin. Invest. (2004) 114(9):1308–1316.
   Google Scholar
• LIU JY, MORRIS GF, LEI WH et al.: Rapid activation of PDGF-A and -B expression at sites of lung injury in asbestos-exposed rats. Am. J. Respir. Cell Md. Biol. (1997) 17(2):129–140.
   PubMed Web of Science ®Google Scholar
• LASKY JA, TONTHAT B, LIU JY, FRIEDMAN M, BRODY AR: Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats. Am. J. Respir. Crit. Care Med. (1998) 157(5 Pt 1):1652–1657.
   PubMed Web of Science ®Google Scholar
• ZHUO Y, ZHANG J, LABOY M, LASKY JA: Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. Am. J. Physiol Lung Cell Md. PhysioL (2004) 286(1):L182–L188.
   PubMed Web of Science ®Google Scholar
• MA CX, HOBDAY TJ, JETT JR: Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin. Proc. (2003) 78(12):1578–1579.
   PubMed Web of Science ®Google Scholar
• ISSHIKI I, YAMAGUCHI K, OKAMOTO S: Interstitial pneumonitis during imatinib therapy. Br. J. Haematol (2004) 125(4):420.
   PubMedGoogle Scholar
• RAJDA J, PHATAK PD: Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Am. J. Hematol (2005) 79(1):80–81.
   PubMed Web of Science ®Google Scholar
• CHARBENEAU RP, PETERS- GOLDEN M: Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin. Sci. (Lond) (2005) 108(6):479–491.
   PubMed Web of Science ®Google Scholar
• WILBORN J, BAILIE M, COFFEY M et al.: Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. Clin. Invest. (1996) 97(8):1827–1836.
   Google Scholar
• BOROK Z, GILLISSEN A, BUHL R et al.: Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am. Rev. Respir. Dis. (1991) 144(5):1080–1084.
   PubMed Web of Science ®Google Scholar
• WILBORN J, CROFFORD LJ, BURDICK MD et al.: Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. j Clin. Invest. (1995) 95(4):1861–1868.
   Google Scholar
• LAMA V, MOORE BB, CHRISTENSEN P, TOEWS GB, PETERS-GOLDEN M: Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am. J. Respir. Cell Md. Biol. (2002) 27(6):752–758.
   PubMed Web of Science ®Google Scholar
• KOHYAMA T, ERTL RF, VALENTI V et al.: Prostaglandin E(2) inhibits fibroblast chemotaxis. Am. J. Physiol. Lung Cell Md. PhysioL (2001) 281(5):L1257–L1263.
   PubMed Web of Science ®Google Scholar
• MIO T, LIU XD, ADACHI Y et al.: Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. Am. J. PhysioL (1998) 274(1 Pt 1):L119–L126.
   PubMed Web of Science ®Google Scholar
• KOLODSICK JE, PETERS-GOLDEN M, LARIOS J et al.: Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mot Biol. (2003) 29(5):537–544.
   PubMed Web of Science ®Google Scholar
• PETERS-GOLDEN M, BAILIE M, MARSHALL T et al.: Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. (2002) 165(2):229–235.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST, PETERS-GOLDEN M, PANETTIERI RA, HENDERSON WR Jr: Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol (2003) 111(1 Suppl.) :S18-534; discussion S34–S36.
   Google Scholar
• IHN H: Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr. Opin. Rheumatol. (2002) 14(6):681–685.
   PubMed Web of Science ®Google Scholar
• DUNCAN MR, FRAZIER KS, ABRAMSON S et al.: Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J (1999) 13(13):1774–1786.
   PubMed Web of Science ®Google Scholar
• BONNIAUD P, MARGETTS PJ, KOLB M et al.: Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis. Am. J. Respir. Crit. Care Med. (2003) 168(7):770–778.
   PubMed Web of Science ®Google Scholar
• SIME PJ, XING Z, GRAHAM FL, CSAKY KG, GAULDIE J: Adenovector-mediated gene transfer of active transforming growth factor-betal induces prolonged severe fibrosis in rat lung. J. Clin. Invest. (1997) 100(4):768–776.
   PubMed Web of Science ®Google Scholar
• LASKY JA, ORTIZ LA, TONTHAT B et al.: Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am. J. PhysioL (1998) 275(2 Pt 1):L365–L371.
   PubMedGoogle Scholar
• ALLEN JT, KNIGHT RA, BLOOR CA, SPITERI MA: Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Cell Md. Biol. (1999) 21(6):693–700.
   PubMed Web of Science ®Google Scholar
• PAN LH, YAMAUCHI K, UZUKI M et al.: Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. (2001) 17(0:1220–1227.
   PubMed Web of Science ®Google Scholar
• SATO S, HASEGAWA M, TAKEHARA K: Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol Sci. (2001) 27(2):140–146.
   PubMed Web of Science ®Google Scholar
• BREWER GJ: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp. Biol. Med. (Maywood) (2001) 226(7):665–673.
   PubMed Web of Science ®Google Scholar
• TANZI RE, PETRUKHIN K, CHERNOV I et al.: The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet. (1993) 5(4):344–350.
   PubMed Web of Science ®Google Scholar
• BREWER GJ, ULLENBRUCH MR, DICK R, OLIVAREZ L, PHAN SH: Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J. Lab. Clin. Med. (2003) 141(3):210–216.
   PubMed Web of Science ®Google Scholar
• BREWER GJ: Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J. Cell Md. Med. (2003) 7(1):11–20.
   PubMed Web of Science ®Google Scholar
• BREWER GJ, DICK R, ULLENBRUCH MR, JIN H, PHAN SH: Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J. Inorg. Biochem. (2004) 98(12):2160–2167.
   PubMed Web of Science ®Google Scholar
• BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N. Engl J. Med. (1994) 331(19):1286–1292.
   PubMed Web of Science ®Google Scholar
• DESMOULIERE A. GEINOZ A, GABBIANI F, GABBIANI G: Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. (1993) 122(1):103–111.
   PubMed Web of Science ®Google Scholar
• TOMASEK JJ, GABBIANI G, HINZ B, CHAPONNIER C, BROWN RA Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev MoL Cell. Biol. (2002) 3(5):349–363.
   PubMed Web of Science ®Google Scholar
• ZHANG HY, PT-JAN SH: Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am. J. Respir. Cell Mol. Biol. (1999) 21(6):658–665.
   Web of Science ®Google Scholar
• JELASKA A, KORN JH: Role of apoptosis and transforming growth factor betal in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum. (2000) 43(10):2230–2239.
   PubMed Web of Science ®Google Scholar
• HOROWITZ JC, LEE DY, WAGHRAY M et al.: Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-betal in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J. Biol. Chem. (2004) 279(2):1359–1367.
   PubMed Web of Science ®Google Scholar
• HAGIMOTO N, KUWANO K, INOSHIMA I et al.: TGF -beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J. ImmunoL (2002) 168(12):6470–6478.
   PubMed Web of Science ®Google Scholar
• WILLIS BC, LIEBLER JM, LUBY-PHELPS K et al.: Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-{beta}l: potential role in idiopathic pulmonary fibrosis. Am. J. PathoL (2005) 166(5):1321–1332.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, TAJIMA H, OKAZAKI H, NAKAMURA T: Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J. Biol. Chem. (1992) 267(35):24917–24920.
   PubMed Web of Science ®Google Scholar
• BHOWMICK NA, CHYTIL A, PLIETH D et al.: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 303(5659):848–851.
   PubMed Web of Science ®Google Scholar
• HAMILTON JA, WOJTA J, GALLICHIO M, MCGRATH K, FILONZI EL: Contrasting effects of transforming growth factor-beta and IL-1 on the regulation of plasminogen activator inhibitors in human synovial fibroblasts. J. Immunol. (1993) 151(10):5154–5161.
   PubMed Web of Science ®Google Scholar
• EDWARDS DR, LECO KJ, BEAUDRY PP et al.: Differential effects of transforming growth factor-beta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Exp. GerontoL (1996) 31(1-2):207–223.
   PubMed Web of Science ®Google Scholar
• BROEKELMANN TJ, LIMPER AH, COLBY TV, MCDONALD JA: Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA (1991) 88(15):6642–6646.
   PubMed Web of Science ®Google Scholar
• KHALIL N, O'CONNOR RN, UNRUH HW et al.: Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am. J. Respir. Cell MoL Biol. (1991) 5(2):155–162.
   PubMed Web of Science ®Google Scholar
• ZHANG K, REKHTER MD, GORDON D, PHAN SH: Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am. J. PathoL (1994) 145(1):114–125.
   PubMed Web of Science ®Google Scholar
• GIRI SN, HYDE DM, HOLLINGER Mk Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax (1993) 48(10):959–966.
   PubMed Web of Science ®Google Scholar
• WANG Q, WANG Y, HYDE DM et al.: Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax (1999) 54(9):805–812.
   PubMed Web of Science ®Google Scholar
• SHIMIZUKAWA M, EBINA M, NARUMI K et al.: Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am. J. PhysioL Lung Cell MoL PhysioL (2003) 284(3):L526–L532.
   PubMed Web of Science ®Google Scholar
• SIRIWARDENA D, KHAW PT, KING AJ et al.: Human antitransforming growth factor beta(2) monoclonal antibody - a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology (2002) 109(3):427–431.
   PubMed Web of Science ®Google Scholar
• SINGH J, LING LE, SAWYER JS et al.: Transforming the TGEbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5). Curr. Opin. Drug Discov. DeveL (2004) 7(4):437–445.
   PubMed Web of Science ®Google Scholar
• SAWYER JS, BEIGHT DW, BRITT KS et al.: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-Npyrazole inhibitors of the transforming growth factor-I3 type I receptor kinase domain. Bioorg Med. Chem. Lett. (2004) 14(13):3581–3584.
   PubMed Web of Science ®Google Scholar
• SINGH J, CHUAQUI CE, BORIACK-SJODIN PA et al.: Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGF-I3 receptor kinase (TbetaRI). Bioorg Med. Chem. Lett. (2003) 13(204355–4359.
   Google Scholar
• BONNIAUD P, MARGETTS PJ, KOLB M et al.: Progressive transforming growth factor Ibetall-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med. (2005) 171(8):889–898.
   PubMed Web of Science ®Google Scholar
• GRYGIELKO ET, MARTIN WM, TWEED CW et al.: Inhibition of gene markers of fibrosis with a novel inhibitor of TGFIbetal-type i receptor kinase in puromycin-induced nephritis. J. PharmacoL Exp. Ther. (2005)
   PubMed Web of Science ®Google Scholar
• DERYNCK R, ZHANG YE: Smad-dependent and Smad-independent pathways in TGF-I3 family signalling. Nature (2003) 425(6958):577–584.
   PubMed Web of Science ®Google Scholar
• ROBERTS AB, DERYNCK R: Meeting report: signaling schemes for TGF-I3. Sci STKE (2001) 2001(113):PE43.
   PubMedGoogle Scholar
• ZHAO J, SHI W, WANG YL et al.: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. PhysioL Lung Cell MoL PhysioL (2002) 282(3):L585–L593.
   PubMed Web of Science ®Google Scholar
• NAKAO A, FUJII M, MATSUMURA R et al.: Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest. (1999) 104(1):5–11.
   PubMed Web of Science ®Google Scholar
• VITTAL R, HOROWITZ JC, MOORE BB et al.: Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am. J. PathoL (2005) 166(2):367–375.
   PubMed Web of Science ®Google Scholar
• JACHIMCZAK P, BOGDAHN U, SCHNEIDER J et al.: The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. Neurosurg (1993) 78(0:944–951.
   Web of Science ®Google Scholar
• WARD MR, SASAHARA T, AGROTIS A et al.: Inhibitory effects of tranilast on expression of transforming growth factor-I3 isoforms and receptors in injured arteries. Atherosclerosis (1998) 137(2):267–275.
   PubMed Web of Science ®Google Scholar
• MURATA H, ZHOU L, OCHOA S et al.: TGF-03 stimulates and regulates collagen synthesis through TGF-betal-dependent and independent mechanisms. J. Invest. Dermatol (1997) 108(3):258–262.
   PubMed Web of Science ®Google Scholar
• BANDYOPADHYAY A, WANG L, LOPEZ-CASILLAS F et al.: Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate (2005) 63(1):81–90.
   PubMed Web of Science ®Google Scholar
• LAMBETH JD: NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol (2004) 4(3):181–189.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.zambongroup.com
   Google Scholar
• http://www.intermune.com
   Google Scholar
• http://www.actelion.com
   Google Scholar
• http://www.coalitionforpf org/IPFResearch
   Google Scholar
• http://www.fibrogen.com
   Google Scholar
• http://www.genzyme.com
   Google Scholar
• http://www.techtransfer.umich.edu
   Google Scholar
• http://www.antisense-pharma.com
   Google Scholar
• http://bioch.szote.u-szeged.hu/astrojan/ protein2.htm
   Google Scholar